Gelteq (GELS) announced a new Gelteq Center of Excellence in Guangdong Province, China, creating a strategic regional hub within a major pharma and biotech ecosystem.
The hub is expected to support accelerated product development and commercialization, expanded formulation and testing capabilities, and greater capacity to advance multiple programs, strengthening Gelteq’s globally integrated platform and international commercial expansion.
Loading…
Loading translation…
AI-generated analysis. Not financial advice.
Positive
- New Center of Excellence established in Guangdong Province, China
- Hub expected to accelerate product development and commercialization timelines
- Expanded formulation, testing, and product optimization capabilities
- Increased capacity to advance multiple development programs simultaneously
- Strategic access to rapidly expanding China biotech and pharma innovation market
- Positioning to participate in cross-border out-licensing market estimated at nearly US$60 billion in Q1 2026
+8.66%
Since News
+12.4%
Peak in 2 min
$0.53
Last Price
$0.48
$0.58
Day Range
+$415K
Valuation Impact
$5.20M
Market Cap
0.3x
Rel. Volume
Following this news, GELS has gained 8.66%, reflecting a notable positive market reaction.
Argus tracked a peak move of +12.4% during the session.
Our momentum scanner has triggered 5 alerts so far, indicating moderate trading interest and price volatility.
The stock is currently trading at $0.53.
This price movement has added approximately $415K to the company’s valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
China out-licensing deals
nearly US$60 billion
Cross-border out-licensing deal value, Q1 2026 (PharmCube estimate)
$0.4841
Last Close
Volume
Volume 8,857 is far below 20-day average 188,338 (relative 0.05), suggesting limited immediate reaction.
low
Technical
Shares at 0.4859 are trading below the 200-day MA of 0.94 and remain heavily discounted vs the 3.51 52-week high.
Scanner data flags a broader Healthcare/biotech move, with 3 peers in momentum (2 down, 1 up; median move about -5.5%). GELS is modestly up 0.37% on very light volume, suggesting today’s China expansion news is more stock-specific than the mixed sector tape.
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 20 |
Veterinary trial start |
Positive |
+19.7% |
Initiation of antiparasitic veterinary clinical trial to support FDA pathway. |
| May 14 |
Earnings update |
Positive |
+0.6% |
Q1 2026 revenue up 73% to $1.6M with positive EBITDA reported. |
| May 12 |
Debt financing |
Negative |
-4.5% |
Up to USD $3.5M strategic debt financing to fund commercialization and trials. |
| Apr 02 |
Prelim results |
Positive |
-8.0% |
Preliminary 2025 results with net revenue up 45% to $4.5M. |
| Feb 11 |
Strategic partnership |
Positive |
-1.4% |
U.S. manufacturing and global distribution partnership for gel-based nutraceuticals. |
Recent Gelteq-specific news often moves the stock, but reactions have been mixed, with some positive fundamental updates sold off while clinical and financing milestones drew more aligned moves.
Over the last few months, Gelteq has reported several milestones: a veterinary clinical trial launch on May 20, 2026 tied to an FDA pathway, strong revenue growth and positive EBITDA at its partner Healthy Extracts on May 14, 2026, and a USD $3.5 million strategic debt financing on May 12, 2026. Earlier, preliminary 2025 revenue growth and a February partnership with Healthy Extracts laid the groundwork for U.S. manufacturing and distribution. The new China Center of Excellence extends this global expansion trajectory.
The stock is surging +10.9% following this news. A strong positive reaction aligns with Gelteq’s pattern of meaningful moves on strategic updates, such as the 19.69% gain after its veterinary clinical trial news. However, the stock still trades well below its 3.51 52-week high and under the 0.94 200-day MA, highlighting prior weakness. Recent convertible financing and Nasdaq bid-price noncompliance add capital-structure and listing risks that could temper or reverse enthusiasm.
out-licensing
financial
“cross-border out-licensing transactions originating from China estimated at nearly US$60 billion”
Out-licensing is when a company grants another firm the right to develop, manufacture or sell a product or technology in exchange for upfront payments, milestone fees and ongoing royalties. Think of it like leasing a recipe to a larger kitchen so they handle production and sales while the original owner collects steady income and reduces costs and risk. For investors, out-licensing can speed commercialization, create near-term revenue, lower development expenses, and shift where future profits and growth will come from.
AI-generated analysis. Not financial advice.
MELBOURNE, Australia, June 04, 2026 (GLOBE NEWSWIRE) — Gelteq Limited (“Gelteq”) today announced the establishment of a new Gelteq Center of Excellence in Guangdong Province, China. The Gelteq Center of Excellence will serve as a strategic regional hub enabling deeper integration with and strategic access to one of the world’s fastest-growing pharmaceutical and biotechnology ecosystems.
Enhancing Development Capabilities Through Regional Hub
The establishment of Gelteq’s Guangdong Province-based Center of Excellence will strengthen the Company’s globally integrated development platform by leveraging regional infrastructure, technical expertise, and established innovation networks.
The hub is expected to support:
- Accelerated product development and commercialization timelines
- Expanded formulation, testing, and product optimization capabilities
- Increased capacity to advance multiple development programs simultaneously
This strategy aligns with approaches adopted by leading global pharmaceutical and biotechnology companies that utilize regional innovation hubs to improve scalability, operational efficiency, and development execution across global pipelines.
It also positions Gelteq to participate in one of the most rapidly expanding biotechnology and pharmaceutical innovation markets globally, which, according to PharmCube, has cross-border out-licensing transactions originating from China estimated at nearly US
“This Center of Excellence represents a significant milestone in expanding Gelteq’s global development and commercial capabilities,” said Nathan Givoni, CEO of Gelteq. “Establishing a strategic presence in China enhances our ability to accelerate product development, strengthen operational scalability, and participate more closely in one of the world’s fastest-growing biotechnology and pharmaceutical innovation ecosystems, where increasing licensing, partnership, and acquisition activity continue to drive global industry interest.”
The Company remains focused on expanding its presence across key international markets that supports both near-term commercial opportunities and long-term pipeline development of products powered by Gelteq® technology.
About Gelteq Ltd.
Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a biotechnology company that has developed a novel drug delivery platform in an ingestible gel form. Gelteq® technology, a propriety delivery technology, is designed to improve how active ingredients are formulated, stabilized and absorbed by the body. Gelteq specializes in research and development, product creation and manufacturing for partners across pharmaceutical, consumer health and animal health markets. Gelteq® technology aims to address challenges associated with conventional drug and nutrient delivery by enhancing bioavailability, improving patient compliance, and enabling precise dosing. For more information, visit www.gelteq.com
Gelteq Contact:
Investor Relations
Matt Kreps, Darrow Associates IR
+1-214-597-8200
mkreps@darrowir.com
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F filed on November 17, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
1 PharmCube. (2026). NextPharma / NextBiopharm Database: China Cross-Border Biopharma Out-Licensing Transactions Tracker.
FAQ
What did Gelteq (GELS) announce on June 4, 2026 about its China operations?
Gelteq announced a new Center of Excellence in Guangdong Province, China. According to Gelteq, this regional hub will enhance development capabilities, commercial expansion, and integration with China’s fast-growing pharmaceutical and biotechnology ecosystem.
What is the purpose of Gelteq’s new Center of Excellence in Guangdong, China (GELS)?
The Center of Excellence will act as a strategic regional hub for Gelteq. According to Gelteq, it is expected to support faster product development, expanded formulation and testing, and simultaneous advancement of multiple development programs within a globally integrated platform.
How could Gelteq’s China Center of Excellence affect product development timelines for GELS?
Gelteq expects the China hub to support accelerated development and commercialization timelines. According to Gelteq, leveraging regional infrastructure, technical expertise, and innovation networks should help optimize formulation, testing, and product advancement across its pipeline.
Why did Gelteq (GELS) choose Guangdong, China for its Center of Excellence?
Gelteq located its hub in Guangdong to access a major biotech and pharma ecosystem. According to Gelteq, China’s market features rapidly growing innovation and nearly US$60 billion of cross-border out-licensing deal value in Q1 2026, per PharmCube.
How does Gelteq’s new China hub support its global commercial expansion strategy (GELS)?
The Center of Excellence is intended to strengthen Gelteq’s global development and commercial capabilities. According to Gelteq, it supports near-term commercial opportunities and long-term pipeline development for products powered by Gelteq technology in key international markets.
